Gregory Alan Korbel - Mar 10, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: SVP, Chief Business Officer, Director
Signature: /s/ Scott M. Coiante, attorney-in-fact
Stock symbol: APRE
Transactions as of: Mar 10, 2022
Transactions value $: -$3,620
Form type: 4
Date filed: 3/14/2022, 05:03 PM
Previous filing: Mar 1, 2022
Next filing: Jun 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+16K	+101%	$0.00	31.8K	Mar 10, 2022	Direct	F1
transaction	APRE	Common Stock	Tax liability	-$3.62K	-1.99K	-6.25%	$1.82	29.9K	Mar 10, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Option (right to Buy)	Award	$0	+72.6K		$0.00	72.6K	Mar 10, 2022	Common Stock	72.6K	$1.82	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units
F3	Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.